<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Molecular. Genetics &amp; Pop Health</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1E0E310-885F-4DC7-B908-31AACD12FAFA"><gtr:id>C1E0E310-885F-4DC7-B908-31AACD12FAFA</gtr:id><gtr:name>Boehringer Ingelheim</gtr:name><gtr:address><gtr:line1>Corporate Division Communications</gtr:line1><gtr:line2>Binger Strasse 173</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5100123F-9727-4CE5-9E59-C6F45E04B3A2"><gtr:id>5100123F-9727-4CE5-9E59-C6F45E04B3A2</gtr:id><gtr:firstName>William</gtr:firstName><gtr:surname>Whiteley</gtr:surname><gtr:orcidId>0000-0002-4816-8991</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902303"><gtr:id>734F9A67-DEA6-47B9-97C5-FA160D2E9A75</gtr:id><gtr:title>Targeted treatment for acute stroke: development of prognostic models and decision support tools</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902303</gtr:grantReference><gtr:abstractText>Stroke, the world?s second biggest killer, is most often due to a blockage of a brain blood vessel by blood clot. Drugs that dissolve clots or prevent them from forming improve the chance of recovery after stroke, but they also increase the chance of bleeding; when bleeds occur into the brain they are particularly severe. Most stroke patients need to take drugs that affect blood clotting at some point in their illness, ranging from potent ?clot busting? drugs to less risky drugs like aspirin.

If a doctor could reliably select which patients were helped rather than harmed by these drugs, this would be a big step forward. I hope to develop a method to predict which stroke patients are more likely to be harmed (by bleeding) than benefit (by avoiding forming blood clots) from medicines that affect clotting. I will use statistical methods to make predictions, and then explore the best way for doctors and patients to use them. This will lead to better decisions for each individual patient, and better treatment policies. This study will use the best information from existing methods as well as from newer technologies (e.g. blood tests and brain imaging) to ensure effective and personalised decisions for each stroke patient</gtr:abstractText><gtr:technicalSummary>Background
Although thrombolytic, antithrombotic and antiplatelet drugs are used for the treatment of acute stroke, they can have severe side effects. Better targeting of these therapies could increase their net population health gain by reducing avoidable haemorrhagic and thrombotic events.

Aim
To develop decision support tools that provide clinically useful guidance and improve patient outcome by better application of existing treatments for stroke. These could be incorporated into the NHS electronic record should they show significant health benefits.

Objectives
1. Develop and validate statistical models to predict haemorrhagic and thrombotic arterial and venous events after stroke with data from a number of large cohorts.
2. Determine whether prediction of haemorrhagic events, based on existing clinical and imaging data, has a significant interaction with the treatment benefits of intravenous thrombolysis, heparin and aspirin in large randomised controlled trials.
3. Create a clinical decision tool, based on the prediction models for haemorrhage and arterial and venous thrombosis developed in parts 1-3
4. Pilot the application of the decision tool in stroke practice in NHS Lothian with a view to establishing a larger scale randomised multi-centre evaluation study.

Design/Methodology
I will develop and validate models for the prediction of haemorrhagic and thrombotic events after stroke in prospective hospital- and community-based cohort studies and randomised controlled trials, from (i) the Stroke Complications and Outcomes Prediction Engine collaboration based in Edinburgh (ii) the Kadoorie Study of Chronic Disease in China and (iii) the Virtual Internet Stroke Archive based in Glasgow 
To examine the interaction between the results of models predicting haemorrhagic and thrombotic events after stroke and the effect of treatment I will use data from the MRC International Stroke Trial of aspirin and heparin, the Third International Stroke Trial of thrombolysis, and the Chinese Acute Stroke Trial of aspirin. 
Using tested technology, in collaboration with a group experienced in health informatics, I will develop a tool to present the results of prognostic models as a clinical decision tool. I will evaluate its feasibility in practice, with a view to a larger study.

Medical and Scientific Opportunities
After stroke, the benefits of antithrombotic and thrombolytic drugs are offset to some extent by an increase in the risk of haemorrhage from the treatment. Better selection of patients for these commonly used treatments could - by focussing treatments on patients most likely to derive net benefit - improve outcome in individual stroke patients, with potentially great population health gains.</gtr:technicalSummary><gtr:fund><gtr:end>2016-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>922163</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Stroke biomarkers University of London</gtr:description><gtr:id>804ABEBA-73DD-4BED-BBA2-6FE23A58B626</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>A7NaQA7psAm-1</gtr:outcomeId><gtr:partnerContribution>Partners are analysing the samples for blood biomarkers of stroke</gtr:partnerContribution><gtr:piContribution>I have contributed patient samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Molecular and Clinical Medicine Edinburgh</gtr:department><gtr:description>Individual patient data meta analysis of heparins</gtr:description><gtr:id>2E6CE966-1D13-418B-9F8A-4298149BD2D2</gtr:id><gtr:impact>Paper in Lancet Neurology</gtr:impact><gtr:outcomeId>hqKKaXjv4KH-2</gtr:outcomeId><gtr:partnerContribution>I have written analysis plan and analysed data</gtr:partnerContribution><gtr:piContribution>Partners have shared data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Individual patient data meta analysis of heparins</gtr:description><gtr:id>9838E5E5-CB35-40C8-9441-4ECB46E46BBF</gtr:id><gtr:impact>Paper in Lancet Neurology</gtr:impact><gtr:outcomeId>hqKKaXjv4KH-1</gtr:outcomeId><gtr:partnerContribution>I have written analysis plan and analysed data</gtr:partnerContribution><gtr:piContribution>Partners have shared data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU)</gtr:department><gtr:description>ATTC</gtr:description><gtr:id>4C6E6282-D558-463C-998A-672DCDC27B48</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>542d4b7111f999.38907446-1</gtr:outcomeId><gtr:partnerContribution>Data, analysis,</gtr:partnerContribution><gtr:piContribution>Drafting proposals, contributing to meetings, joining an ongoing collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Institute of Clinical Medicine</gtr:department><gtr:description>Individual patient data meta analysis of heparins</gtr:description><gtr:id>E5B94E19-85FA-47BE-BE18-E70DDDC0EF07</gtr:id><gtr:impact>Paper in Lancet Neurology</gtr:impact><gtr:outcomeId>hqKKaXjv4KH-4</gtr:outcomeId><gtr:partnerContribution>I have written analysis plan and analysed data</gtr:partnerContribution><gtr:piContribution>Partners have shared data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boehringer Ingelheim</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Stroke Thrombolysis Trialists Collaboration</gtr:description><gtr:id>C22F9DBE-8C2C-4D97-91DF-D63F91CD7CC8</gtr:id><gtr:impact>Study protocol published in International Journal of Stroke
First manuscript in preparation</gtr:impact><gtr:outcomeId>iGSENCV7XzJ-2</gtr:outcomeId><gtr:partnerContribution>Statistical analysis and hosting of dataset</gtr:partnerContribution><gtr:piContribution>Contributed to papers and editing of data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Informatics Edinburgh</gtr:department><gtr:description>Natural language processing for brain imaging reports</gtr:description><gtr:id>7BFC134C-6242-4FEF-B460-49713808B7F7</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>542d6b2ee92661.57736391-1</gtr:outcomeId><gtr:partnerContribution>Natural language processing</gtr:partnerContribution><gtr:piContribution>A collaboration to determine whether brain imaging features in radiology reports can be identified by natural language processing. I have identified a means of obtaining scans from routinely collected data, and built a case for their use with epidemiological datasets.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Iowa</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>Individual patient data meta analysis of heparins</gtr:description><gtr:id>CBA6AC8E-1E7D-4639-ABA2-51985885945A</gtr:id><gtr:impact>Paper in Lancet Neurology</gtr:impact><gtr:outcomeId>hqKKaXjv4KH-3</gtr:outcomeId><gtr:partnerContribution>I have written analysis plan and analysed data</gtr:partnerContribution><gtr:piContribution>Partners have shared data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Academy of Medical Sciences Developing a career in academic medicine</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>814BE50B-C5F4-49CC-97DD-8AA718E9B413</gtr:id><gtr:impact>Discussed working in large teams in a joint presentation with Prof. Phillpa Saunders

Interest from academic trainees in working in team based science, and publicising Academy's survey on team based science</gtr:impact><gtr:outcomeId>5437c0a1296f34.56183076</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.acmedsci.ac.uk/more/events/developing-a-career-in-academic-medicine-edinburgh/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Autumn School, Edinburgh Neuroscience</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C969F69F-2E13-486B-AA88-D0B2481E74B1</gtr:id><gtr:impact>Educating post-graduate researchers in careers and research methods. My involvement was to deliver a lecture, and planning a session

Continuing support to Neuroscience students in Edinburgh</gtr:impact><gtr:outcomeId>5437bd751f3896.89764537</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BMJ Masterclass</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>196AEE33-9FCB-469B-BCED-5D89980B9729</gtr:id><gtr:impact>BMJ Stroke Masterclass. Invited to speak about work to 90 Stroke physicians in UK.

98% felt the talk was good or excellent.</gtr:impact><gtr:outcomeId>542d6f6180ce29.67658641</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://masterclasses.bmj.com/physician-courses/stroke</gtr:url><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture on thrombolysis to Royal College of Physicians and Surgeons, Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>87FD894A-C601-44B9-BD91-2E2C41FD3E00</gtr:id><gtr:impact>Education day in stroke and thrombolysis</gtr:impact><gtr:outcomeId>56d480c5d73357.41667959</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ABN research day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B3930A31-236E-4F07-91CF-36A90EDF8A18</gtr:id><gtr:impact>Talking to UK neurology registrars about the way into a career in research

Continued interest from neurology registrars in my research area. Excellent feedback.</gtr:impact><gtr:outcomeId>542d70466038a4.82262677</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7C9F279A-B895-4A13-9A42-37B963D8D770</gtr:id><gtr:impact>30 pupils talking about careers in research and medicine

Continuing interest from pupils and parents</gtr:impact><gtr:outcomeId>542d6fb2413913.19763690</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Development of a smartphone App for FAST test communication</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>95E8F057-6E93-45E5-939B-D2C5DCBB6BC9</gtr:id><gtr:impact>We have developed an iPhone/Android telephone App with Chest Heart and Stroke Scotland to educate the public about the FAST test. The FAST test is a method for early identification of patients with stroke by members of the general public. It is due to be rolled out to the i Store and Google app store in early December 2011.

Rolled out, led to media coverage on Scottish TV and national newspapers, and featured in the MRC annual report. The app has been downloaded ~1,400 times.</gtr:impact><gtr:outcomeId>hWLqEiyVfpa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://play.google.com/store/apps/details?id=com.chss.fasttest&amp;hl=en</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Stroke Day Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4FDFC460-E1F5-4936-8D47-FE74C90EE4AF</gtr:id><gtr:impact>I lectured on access to medicines to prevent stroke as part of a WSO Stroke Day event, sponsored by Edinburgh Global Health Academy and Edinburgh Neuroscience

Education of Edinburgh public about the poor access to medicines. No specific metric.</gtr:impact><gtr:outcomeId>5633b505959f44.77576358</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.eventbrite.co.uk/e/access-to-medicines-the-global-story-of-strokes-tickets-18848177406</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>190198</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Princess Margaret Research Development Fellowship</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Stroke Association</gtr:fundingOrg><gtr:fundingRef>TSA PMF 2013/03</gtr:fundingRef><gtr:id>BF450F0A-392C-429E-8465-60C0FA231A99</gtr:id><gtr:outcomeId>RfuYxE6UgXp</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Chest Heart and Stroke Scotland Small Grants</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Chest Heart &amp; Stroke Scotland</gtr:fundingOrg><gtr:id>F9CEF3C6-3554-4482-9BB1-4F0964C13BDE</gtr:id><gtr:outcomeId>Q5ohrqUrWBj0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Cited as evidence in MHRA planned review of medication</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2ADD4450-3648-46DE-BB29-2637A4F7F03E</gtr:id><gtr:impact>The MHRA is reviewing their policy on the drug alteplase after multiple depositions by interested clinicians. Our systematic review will be a key piece of evidence to show that the drug is useful. The results of the review are not yet known (expected 2015)</gtr:impact><gtr:outcomeId>5436b922e13da4.50552860</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>http://www.mhra.gov.uk/NewsCentre/CON448382</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Embolic Stroke of Uncertain Source Scientific Panel</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>49E0133F-6B80-4B2C-ACB5-639C6F707C01</gtr:id><gtr:outcomeId>5437c1d4978a14.66863084</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>We aim to present the results of predictions about the prognosis of stroke patients to junior doctors on a smartphone. 

We have developed a smartphone application that is in its final stages of development and will go to the iStore in early 2012.</gtr:description><gtr:id>80B39AD9-9470-4BA0-8850-05172DA81FF8</gtr:id><gtr:impact>As yet none, other than the experience gained by one of the programmers in the department.</gtr:impact><gtr:outcomeId>oeyASAvf7sU</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>iPhone App for presentation of the results of predicted outcome of stroke patients to junior doctors</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>An iPhone application to educate member of the public about the use of the FAST test. The programming aspects of this work have been supported b the CHSS (see the small grant section), in collaboration with NHS24 and the Scottish Ambulance Service. My time has been supported by my MRC Clinician Scientist Fellowship.</gtr:description><gtr:id>AE29152D-B558-435E-95DC-107D81FAF346</gtr:id><gtr:impact>The development process has been important experience for one of the department's programmers in mobile computing. This work will be rolled out to the public in late 2011/early 2012 with possibility of further work with heart attack and other medical emergencies.</gtr:impact><gtr:outcomeId>k2eAti1yemu</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>iPhone App for public education about the FAST test for the early identification of stroke</gtr:title><gtr:type>Health and Social Care Services</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>A database held within the University of Oxford and the University of Alabama with all data from randomised controlled trials of alteplase</gtr:description><gtr:id>9D28991B-5B6D-4FBC-9D44-ACFD506994D4</gtr:id><gtr:impact>Lancet paper</gtr:impact><gtr:outcomeId>5437c27e979ff8.98378087</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Stroke Thrombolysis Trialists Collaboration</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://www.ctsu.ox.ac.uk/research/meta-trials/stt-1</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>36B6AF02-C5A3-4D0D-815C-FE02FD237022</gtr:id><gtr:title>How well do standard stroke outcome measures reflect quality of life? A retrospective analysis of clinical trial data.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dddfdaf440109f7e232cca893849617"><gtr:id>9dddfdaf440109f7e232cca893849617</gtr:id><gtr:otherNames>Ali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_12549_29_24052510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DDB9CD5-E259-49DE-9908-E9E15ECE599E</gtr:id><gtr:title>Stroke Prevalence, Mortality and Disability-Adjusted Life Years in Children and Youth Aged 0-19 Years: Data from the Global and Regional Burden of Stroke 2013.</gtr:title><gtr:parentPublicationTitle>Neuroepidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea7e3db759b409797d47faf1eb02e2ab"><gtr:id>ea7e3db759b409797d47faf1eb02e2ab</gtr:id><gtr:otherNames>Krishnamurthi RV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0251-5350</gtr:issn><gtr:outcomeId>56d47d0dc82fe1.88168105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>335826AE-7E23-44D3-A33C-A69371487BF0</gtr:id><gtr:title>Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis</gtr:title><gtr:parentPublicationTitle>The Lancet Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e5e9cd102979ad42c3c043c5c1088d"><gtr:id>e0e5e9cd102979ad42c3c043c5c1088d</gtr:id><gtr:otherNames>Whiteley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d457068ee21.23790351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F819379-E0EB-4575-B888-A889658E4B18</gtr:id><gtr:title>Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_12549_29_22996959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63BE2A26-A7A2-4AEC-837F-7400BCEE1B12</gtr:id><gtr:title>Transient ischemic attack incidence in joinville, Brazil, 2010: a population-based study.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2333f3640f19542d6e0cd1398b0e03a3"><gtr:id>2333f3640f19542d6e0cd1398b0e03a3</gtr:id><gtr:otherNames>Fonseca PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>pm_12549_29_22207503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD592F07-90E4-48D4-9C4E-0C2F4724C86F</gtr:id><gtr:title>How individual participant data meta-analyses have influenced trial design, conduct, and analysis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663c60b99db378e47bc2ef1efd6bb108"><gtr:id>663c60b99db378e47bc2ef1efd6bb108</gtr:id><gtr:otherNames>Tierney JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>56d47d0eb431d2.31288656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27170FEB-2ADD-473F-9828-4B77A591439D</gtr:id><gtr:title>The Heidelberg Bleeding Classification: Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d57f5abfeaad1c50174a6af39ad7530b"><gtr:id>d57f5abfeaad1c50174a6af39ad7530b</gtr:id><gtr:otherNames>von Kummer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>55fa8da4775744.59480214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E2BE5A1-F692-47DF-A449-9BB9B73CDD11</gtr:id><gtr:title>More outcomes than trials: a call for consistent data collection across stroke rehabilitation trials.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dddfdaf440109f7e232cca893849617"><gtr:id>9dddfdaf440109f7e232cca893849617</gtr:id><gtr:otherNames>Ali M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>pm_12549_29_23280265</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F90F2EB8-2718-42D5-8488-55079FC5064A</gtr:id><gtr:title>Functional status three months after the first ischemic stroke is associated with long-term outcome: data from a community-based cohort.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3441cc85c62561344df493a788d87e03"><gtr:id>3441cc85c62561344df493a788d87e03</gtr:id><gtr:otherNames>Magalh?es R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>542d362bd3bf98.37385313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7D47CD4-146E-4644-91FD-2423B402F731</gtr:id><gtr:title>Comparison of statistical and clinical predictions of functional outcome after ischemic stroke.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21a9944b6062ae4454025970fd10809"><gtr:id>d21a9944b6062ae4454025970fd10809</gtr:id><gtr:otherNames>Thompson DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_55f945294525f143b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6CDCB51-3408-4AA0-8FFC-63D0C7D1D23A</gtr:id><gtr:title>Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e8f84cffa8d60c2e0b79feeafd6061b"><gtr:id>6e8f84cffa8d60c2e0b79feeafd6061b</gtr:id><gtr:otherNames>Mair G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>56d47d0c691747.33226167</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A41086FE-6F65-4976-9714-2E0967D04A92</gtr:id><gtr:title>Do acute phase markers explain body temperature and brain temperature after ischemic stroke?</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12549_29_22744672</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06C8803B-A4B4-4414-87A2-F03103EC5EE1</gtr:id><gtr:title>Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial).</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>55fa8e1479cce7.51044962</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC340F2B-341E-4921-A45B-0310AC6E59FF</gtr:id><gtr:title>Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12c7afbed82d8caa4bccf507dbc328ea"><gtr:id>12c7afbed82d8caa4bccf507dbc328ea</gtr:id><gtr:otherNames>IST-3 collaborative group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12549_29_23791822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2793CFBD-19FA-4F94-826F-72E11A7F599B</gtr:id><gtr:title>Mortality after thrombolysis - Authors' reply.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/889459a7ee599cec60bedb06624900f0"><gtr:id>889459a7ee599cec60bedb06624900f0</gtr:id><gtr:otherNames>Berge E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>58bf2d5a63ccc4.71907813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B52E090F-F6B7-41FD-9898-1538C4D63E7C</gtr:id><gtr:title>Clinical scores for the identification of stroke and transient ischaemic attack in the emergency department: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>WGvcRSFAPzr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A7D92B2-CC8D-477F-9FEB-8608CB5F19A2</gtr:id><gtr:title>Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>55fa8da33d9788.90853300</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37583726-B559-4652-8178-01126CF9ADD8</gtr:id><gtr:title>Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/889459a7ee599cec60bedb06624900f0"><gtr:id>889459a7ee599cec60bedb06624900f0</gtr:id><gtr:otherNames>Berge E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>56d47d0e8a9663.52452349</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA3B0025-9DC9-46E4-A072-20EC8E764B6F</gtr:id><gtr:title>Blood biomarkers for the diagnosis of acute cerebrovascular diseases: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e5e9cd102979ad42c3c043c5c1088d"><gtr:id>e0e5e9cd102979ad42c3c043c5c1088d</gtr:id><gtr:otherNames>Whiteley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>AhE7p2XYqBo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EB00B1B-DD14-4DD0-9693-3F94D1FAAE34</gtr:id><gtr:title>Identifying blood biomarkers to improve the diagnosis of stroke.</gtr:title><gtr:parentPublicationTitle>The journal of the Royal College of Physicians of Edinburgh</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e5e9cd102979ad42c3c043c5c1088d"><gtr:id>e0e5e9cd102979ad42c3c043c5c1088d</gtr:id><gtr:otherNames>Whiteley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1478-2715</gtr:issn><gtr:outcomeId>STF63Bk94Ni</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E38AFD10-69F7-4237-8799-44C0DA44428D</gtr:id><gtr:title>Reduce, reuse and recycle.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0d282db15d36d37108047ff295ed92e"><gtr:id>e0d282db15d36d37108047ff295ed92e</gtr:id><gtr:otherNames>Brady MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>AQULbw97Weg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5308084D-F0EE-423D-A896-E8066C47F5DC</gtr:id><gtr:title>Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>pm_12549_29_22405276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09219805-6AD6-4FF6-A028-50BD45267B2F</gtr:id><gtr:title>Formal and informal prediction of recurrent stroke and myocardial infarction after stroke: a systematic review and evaluation of clinical prediction models in a new cohort.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21a9944b6062ae4454025970fd10809"><gtr:id>d21a9944b6062ae4454025970fd10809</gtr:id><gtr:otherNames>Thompson DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>54252e29029fe0.37119118</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EEDDB86-A90A-4607-8CCA-11917784C529</gtr:id><gtr:title>Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da90cc45e04dfc83bfec5febb3041423"><gtr:id>da90cc45e04dfc83bfec5febb3041423</gtr:id><gtr:otherNames>Stroke Thrombolysis Trialists' Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>54252e28c49880.22829018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF1AB63C-5E65-4299-BB0D-8B1781D39CEB</gtr:id><gtr:title>Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00ab49571f031de743ed7cffc95455ea"><gtr:id>00ab49571f031de743ed7cffc95455ea</gtr:id><gtr:otherNames>Hacke W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>5a9e6268db9e17.27248618</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35F8322E-730C-4655-AB55-4E63DB8BD63E</gtr:id><gtr:title>Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Journal of neuroimmunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3e0819024a1a66d75a0826e699621f"><gtr:id>fc3e0819024a1a66d75a0826e699621f</gtr:id><gtr:otherNames>Bustamante A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0165-5728</gtr:issn><gtr:outcomeId>542d362c7881d5.77165689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17246000-0070-4DEF-9B4F-3D3685D176D9</gtr:id><gtr:title>Response to letter regarding article, &amp;quot;Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial&amp;quot;.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>542d362ca659f9.16342162</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1BCBEF3-82CF-473A-A467-C060C5D7A9AD</gtr:id><gtr:title>The differential diagnosis of suspected stroke: a systematic review.</gtr:title><gtr:parentPublicationTitle>The journal of the Royal College of Physicians of Edinburgh</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d5d3da7805e7ba8945127c1533ecb04"><gtr:id>5d5d3da7805e7ba8945127c1533ecb04</gtr:id><gtr:otherNames>Gibson LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1478-2715</gtr:issn><gtr:outcomeId>pm_12549_29_23734351</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>938E94D0-E390-4880-8BE7-B9831EE21B12</gtr:id><gtr:title>Alteplase for ischaemic stroke--responses.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>542d362c1114c5.14530946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCBAAC40-0DC6-42D8-B72E-43566FD33C93</gtr:id><gtr:title>Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d92ef546ea273952a7cfddeb17749e"><gtr:id>27d92ef546ea273952a7cfddeb17749e</gtr:id><gtr:otherNames>Emberson J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>542d362c4a71d1.69071872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC6A8DF5-9780-4296-BC46-212755D64EC7</gtr:id><gtr:title>Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7f53abbd2857ddb15bd313e00c73cef5"><gtr:id>7f53abbd2857ddb15bd313e00c73cef5</gtr:id><gtr:otherNames>Lees KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>58bf2d5abf14a5.47921057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DB29C91-0F41-42DF-87AA-D03137D4D30D</gtr:id><gtr:title>Parenteral fluid regimens for improving functional outcome in people with acute stroke.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/860f8fc7664c3b4306dcf343aeee1d49"><gtr:id>860f8fc7664c3b4306dcf343aeee1d49</gtr:id><gtr:otherNames>Visvanathan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>55fa8da43daff4.71169564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5499A502-23D3-4A0B-B079-08AEA93F4BB3</gtr:id><gtr:title>Anticoagulation Timing for Atrial Fibrillation in Acute Ischemic Stroke: Time to Reopen Pandora's Box?</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/73af0fe147efd339a98b5d412d5559bf"><gtr:id>73af0fe147efd339a98b5d412d5559bf</gtr:id><gtr:otherNames>Ng KKH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>5a9e62691f1815.63504187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F13CF2E-0984-4736-A9A5-6AF5E58CF404</gtr:id><gtr:title>Association of circulating inflammatory markers with recurrent vascular events after stroke: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e5e9cd102979ad42c3c043c5c1088d"><gtr:id>e0e5e9cd102979ad42c3c043c5c1088d</gtr:id><gtr:otherNames>Whiteley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>nNXNjZUCrDb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F66E572F-24B3-4A20-B8D5-CDA0E561DC7A</gtr:id><gtr:title>Author response.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6d4944da6060d033e7b78eb9c8749e1"><gtr:id>a6d4944da6060d033e7b78eb9c8749e1</gtr:id><gtr:otherNames>Wardlaw JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_12549_29_23544195</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C924E407-9EEC-47C8-8FA5-302AF32384AA</gtr:id><gtr:title>Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12549_29_23642343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>215F13E1-7F8B-46D8-A032-631941509678</gtr:id><gtr:title>Interventions for post-stroke fatigue.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d93e0d9984e7d52bb28236d6ce868b44"><gtr:id>d93e0d9984e7d52bb28236d6ce868b44</gtr:id><gtr:otherNames>Wu S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>55fa95ccb54897.77615391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B69E8906-938A-441B-B5EE-137423085BF1</gtr:id><gtr:title>Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12c7afbed82d8caa4bccf507dbc328ea"><gtr:id>12c7afbed82d8caa4bccf507dbc328ea</gtr:id><gtr:otherNames>IST-3 collaborative group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>55fa8da39d9870.18909738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B73D326F-7DA8-4BEA-9D7B-FC88B500DEEB</gtr:id><gtr:title>Covariate adjustment had similar benefits in small and large randomized controlled trials.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21a9944b6062ae4454025970fd10809"><gtr:id>d21a9944b6062ae4454025970fd10809</gtr:id><gtr:otherNames>Thompson DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>55fa8da3026d09.93105373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C9E8294-9CCD-4184-B8E0-70BD98BEEB32</gtr:id><gtr:title>Outcome after conservative management or intervention for unruptured brain arteriovenous malformations.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/465202a0e76a70c877a9acff11c95c35"><gtr:id>465202a0e76a70c877a9acff11c95c35</gtr:id><gtr:otherNames>Al-Shahi Salman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>542d362cd952e1.22013314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA0F566B-83B5-4360-B7A1-8482C0AED216</gtr:id><gtr:title>Blood biomarkers in stroke: research and clinical practice.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e5e9cd102979ad42c3c043c5c1088d"><gtr:id>e0e5e9cd102979ad42c3c043c5c1088d</gtr:id><gtr:otherNames>Whiteley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>pm_12549_29_22463131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B69B5BDB-837D-4717-B6BA-45A72DAB00B4</gtr:id><gtr:title>Correlation of levels of neuronal and glial markers with radiological measures of infarct volume in ischaemic stroke: a systematic review.</gtr:title><gtr:parentPublicationTitle>Cerebrovascular diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e231ab910043095752b8104914c03ba3"><gtr:id>e231ab910043095752b8104914c03ba3</gtr:id><gtr:otherNames>Ahmad O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn><gtr:outcomeId>pm_12549_29_22133844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42B71110-1CBE-4566-B21D-B21FD4693D27</gtr:id><gtr:title>Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd709aad3f5a6eca29e8d074bee23e6a"><gtr:id>dd709aad3f5a6eca29e8d074bee23e6a</gtr:id><gtr:otherNames>Sandercock P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_12549_29_22129158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37DEC8B6-31FE-47AB-87B5-2891B1F163A4</gtr:id><gtr:title>The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12c7afbed82d8caa4bccf507dbc328ea"><gtr:id>12c7afbed82d8caa4bccf507dbc328ea</gtr:id><gtr:otherNames>IST-3 collaborative group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_12549_29_22632908</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E7A529F-9B8E-46B3-B0D0-F9A59CFD5219</gtr:id><gtr:title>Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21a9944b6062ae4454025970fd10809"><gtr:id>d21a9944b6062ae4454025970fd10809</gtr:id><gtr:otherNames>Thompson DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>55fa8da3ca6478.04490934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F69393C7-DF0F-4D81-B973-572FB2FB81AD</gtr:id><gtr:title>Hoover's sign for the diagnosis of functional weakness: a prospective unblinded cohort study in patients with suspected stroke.</gtr:title><gtr:parentPublicationTitle>Journal of psychosomatic research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b3fb306d5a752094c2e6104533e3ff76"><gtr:id>b3fb306d5a752094c2e6104533e3ff76</gtr:id><gtr:otherNames>McWhirter L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3999</gtr:issn><gtr:outcomeId>sBbJRXHDQEY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D3261A6-4AD6-4418-8AB5-C1777BC3E48F</gtr:id><gtr:title>Computed tomography and magnetic resonance perfusion imaging in ischemic stroke: definitions and thresholds.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a891b124da452d7be6028107d76c80d"><gtr:id>2a891b124da452d7be6028107d76c80d</gtr:id><gtr:otherNames>Dani KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>Y3rzD83xrLq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDCA8E77-384A-4707-9D55-594DC2CF83DA</gtr:id><gtr:title>Strokes: mimics and chameleons.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4481ca1393b021ab022de27067a7e1d"><gtr:id>c4481ca1393b021ab022de27067a7e1d</gtr:id><gtr:otherNames>Fernandes PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>pm_12549_29_23315456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1853ACAE-655B-4958-B462-672F679A62B9</gtr:id><gtr:title>Short term exposure to air pollution and stroke: systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/845508d8fadfd63ae3f141635179a4cb"><gtr:id>845508d8fadfd63ae3f141635179a4cb</gtr:id><gtr:otherNames>Shah AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>55fa8da36b0708.19825122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7002C55B-D06F-4308-81DD-BF88CA575DDD</gtr:id><gtr:title>The Brazilian Family Health Program and secondary stroke and myocardial infarction prevention: a 6-year cohort study.</gtr:title><gtr:parentPublicationTitle>American journal of public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab0662deaac92596fb33cb8faef90d3d"><gtr:id>ab0662deaac92596fb33cb8faef90d3d</gtr:id><gtr:otherNames>Cabral NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0090-0036</gtr:issn><gtr:outcomeId>pm_12549_29_23078478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEE37086-691C-4E90-85B8-E9F1780A854F</gtr:id><gtr:title>B-type natriuretic peptides and mortality after stroke: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1c7b5d5c8677fcf5cdc27662e70496ff"><gtr:id>1c7b5d5c8677fcf5cdc27662e70496ff</gtr:id><gtr:otherNames>Garc?a-Berrocoso T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>542d362d48d9b5.41044835</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBB3BC2E-8540-43E8-BDB2-3DAFD407D055</gtr:id><gtr:title>Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53eb0e856a7f3b3e6ce1c14558548cda"><gtr:id>53eb0e856a7f3b3e6ce1c14558548cda</gtr:id><gtr:otherNames>Lindley RI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>56d47d0f167d59.02966748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5375364B-C80F-4CBC-BEB9-5FC94E84E447</gtr:id><gtr:title>Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f67a36f4c44c4922a18eaf376974507b"><gtr:id>f67a36f4c44c4922a18eaf376974507b</gtr:id><gtr:otherNames>Whiteley WN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>542d362d19c398.12561452</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AD21013-62B6-4447-B428-E8290E5704B2</gtr:id><gtr:title>Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/465202a0e76a70c877a9acff11c95c35"><gtr:id>465202a0e76a70c877a9acff11c95c35</gtr:id><gtr:otherNames>Al-Shahi Salman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_12549_29_22297119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8875437E-28C9-49B0-AA90-CEB48FA74C58</gtr:id><gtr:title>The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0e5e9cd102979ad42c3c043c5c1088d"><gtr:id>e0e5e9cd102979ad42c3c043c5c1088d</gtr:id><gtr:otherNames>Whiteley W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>GrN5J5e8aLR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E8ABF84-C466-4068-80A9-A9FC79BD3098</gtr:id><gtr:title>Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/889459a7ee599cec60bedb06624900f0"><gtr:id>889459a7ee599cec60bedb06624900f0</gtr:id><gtr:otherNames>Berge E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>58bf2d5b09db86.64070548</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902303</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>B7F5A9CA-62C7-4E68-A2B2-3D6CCA85E16B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>7.3  Management and decision making</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>